Tuesday, January 17, 2017

HCV Next Cover Story - 2017 A Year in Transition

2017: A Year in Transition

"HCV Next" features cutting edge news on the latest HCV research developments. With in-depth articles on a range of topics; diagnosis, hepatitis c treatment regimens, side effects, drug/drug interaction, guidelines, practice management issues, to name a few.

The following articles appeared in the January 2017 print edition of HCV NEXT, provided online at Healio.

Table of Contents
5 Questions
A Conversation With Robert Gish, MD

Cover Story
2017: A Year in Transition
Cover Story     
Throughout 2016, the remarkable success of direct-acting agents was confirmed and extended. Several new drugs — including Epclusa (Gilead), Zepatier (Merck), Daklinza (Bristol-Myers Squibb), Technivie (AbbVie), Viekira Pak (AbbVie) and Viekira XR (AbbVie) — were approved, representing continued remarkable potency of the DAA agents with the added bonus of extension into more pangenotypic activity. While there are still many other new drugs in development with the same trend toward increased potency and pangenotypic activity, it seems that drug development is starting to plateau. This ultimately will leave us with a strong armamentarium from which to choose the best agents for each of our individual patients.

Michael S. Saag, MD
Drug Pipeline
HCV 2016 Timeline

No comments:

Post a Comment